BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announces a KOL webinar scheduled for December 11, 2024, at 10:00 AM ET, focusing on Amyotrophic Lateral Sclerosis (ALS) treatment developments. The event will feature Dr. Terry Heiman-Patterson from Temple University's Lewis Katz School of Medicine, who will discuss the current ALS treatment landscape. BrainStorm's management will provide updates on their planned Phase 3b registrational clinical trial for NurOwn® (autologous MSC-NTF cells) and future development plans. The successful completion of Part A of the Phase 3b trial is expected to support a Biologic License Application (BLA) for NurOwn. The webinar will conclude with a live Q&A session.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) annuncia un webinar con esperti del settore programmato per l'11 dicembre 2024, alle 10:00 ET, incentrato sui sviluppi nel trattamento della Sclerosi Laterale Amiotrofica (SLA). L'evento presenterà il Dr. Terry Heiman-Patterson della Lewis Katz School of Medicine della Temple University, che discuterà l'attuale panorama dei trattamenti per la SLA. La direzione di BrainStorm fornirà aggiornamenti sul piano di sperimentazione clinica registrativa in fase 3b per NurOwn® (cellule MSC-NTF autologhe) e sui progetti di sviluppo futuri. Il completamento con successo della Parte A della sperimentazione clinica in fase 3b dovrebbe sostenere una Richiesta di Licenza Biologica (BLA) per NurOwn. Il webinar si concluderà con una sessione di domande e risposte dal vivo.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) anuncia un webinar de KOL programado para el 11 de diciembre de 2024, a las 10:00 AM ET, enfocado en los desarrollos del tratamiento de la Esclerosis Lateral Amiotrófica (ELA). El evento contará con la participación del Dr. Terry Heiman-Patterson de la Lewis Katz School of Medicine de la Temple University, quien discutirá el panorama actual del tratamiento de la ELA. La dirección de BrainStorm proporcionará actualizaciones sobre su ensayo clínico registrativo de fase 3b para NurOwn® (células MSC-NTF autólogas) y sus planes de desarrollo futuros. Se espera que la conclusión exitosa de la Parte A del ensayo de fase 3b respalde una Solicitud de Licencia Biológica (BLA) para NurOwn. El webinar finalizará con una sesión de preguntas y respuestas en vivo.
브레인스톰 셀 치료제 (NASDAQ: BCLI)는 2024년 12월 11일 오전 10:00 ET에 예정된 KOL 웨비나를 발표하며, 근위축성 측삭 경화증 (ALS) 치료 개발에 초점을 맞춥니다. 이 행사에는 템플 대학교 루이스 카츠 의과대학의 테리 하이먼-패터슨 박사가 참여하여 현재 ALS 치료의 지형에 대해 논의할 것입니다. 브레인스톰의 경영진은 NurOwn® (자가 유래 MSC-NTF 세포)에 대한 예정된 3b상 등록 임상 시험 및 향후 개발 계획에 대한 업데이트를 제공합니다. 3b상 시험의 A 부분이 성공적으로 완료되면 NurOwn에 대한 생물학적 라이센스 신청서 (BLA)를 지원할 것으로 예상됩니다. 웨비나는 라이브 Q&A 세션으로 마무리될 것입니다.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) annonce un webinaire KOL prévu pour le 11 décembre 2024 à 10h00 ET, centré sur les développements des traitements de la Sclérose Latérale Amyotrophique (SLA). L'événement mettra en vedette le Dr Terry Heiman-Patterson de la Lewis Katz School of Medicine de l'Université Temple, qui discutera du paysage actuel du traitement de la SLA. La direction de BrainStorm fournira des mises à jour sur leur essai clinique d'enregistrement de phase 3b prévu pour NurOwn® (cellules MSC-NTF autologues) et sur leurs plans de développement futurs. L'achèvement réussi de la Partie A de l'essai de phase 3b devrait soutenir une Demande de Licence Biologique (BLA) pour NurOwn. Le webinaire se terminera par une session de questions-réponses en direct.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) kündigt ein KOL-Webinar an, das am 11. Dezember 2024 um 10:00 Uhr ET stattfindet und sich auf Entwicklungen der Behandlung von Amyotropher Lateralsklerose (ALS) konzentriert. Bei der Veranstaltung wird Dr. Terry Heiman-Patterson von der Lewis Katz School of Medicine der Temple University sprechen und den aktuellen Stand der ALS-Behandlung vorstellen. Das Management von BrainStorm wird Updates zu ihrer geplanten Phase-3b-Zulassungsstudie für NurOwn® (autologe MSC-NTF-Zellen) und zukünftige Entwicklungspläne geben. Der erfolgreiche Abschluss von Teil A der Phase-3b-Studie wird voraussichtlich eine Biologikantrag (BLA) für NurOwn unterstützen. Das Webinar wird mit einer Live-Q&A-Sitzung enden.
- None.
- None.
The webinar will feature Dr. Terry Heiman-Patterson, a KOL from the Lewis Katz School of Medicine at Temple University, who will discuss the current treatment landscape and advances for patients with amyotrophic lateral sclerosis (ALS). Dr. Heiman-Patterson will be joined by BrainStorm's management team, who will share updates on the company's planned Phase 3b registrational clinical trial, NurOwn® (autologous MSC-NTF cells), and future development plans.
Successful completion of the randomized portion (Part A) of the Phase 3b trial is expected to support a Biologic License Application (BLA) for NurOwn.
A live Q&A session will follow the formal presentations.
About Terry Heiman-Patterson, MD
Dr. Terry Heiman-Patterson is a pioneering figure in ALS care and research, with a career spanning decades of groundbreaking contributions to neurology. She is the Director of the Center for Neurodegenerative Disorders and a Professor in the Department of Neurology at the Lewis Katz School of Medicine at Temple University. Previously, she held esteemed roles as Vice Chair of the Department of Neurology, Director of the Division of Neuromuscular Disease, and Professor of Neurology at Drexel University College of Medicine in
For over 20 years, Dr. Heiman-Patterson directed the MDA/ALS Center of Hope at Drexel, and for more than 30 years, she led the outpatient Muscular Dystrophy Clinic at Good Shepherd Rehabilitation Center in
Dr. Terry Heiman-Patterson has spearheaded 24 clinical trials, establishing key standards in ALS care. She has authored more than 50 groundbreaking papers on motor neuron diseases and published hundreds of papers, abstracts, and book chapters on ALS and related disorders. Her work has earned national and international acclaim, including the prestigious Forbes Norris Award for her dedication to improving ALS patient care and advancing research
Dr. Heiman-Patterson earned her medical degree at Albany Medical College in
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the probability of NurOwn demonstrating a treatment effect in ALS, the patient enrollment and dosing in the Phase 3b trial for NurOwn®, and the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
IR:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:SOURCE BrainStorm Cell Therapeutics Inc.
FAQ
When is BrainStorm Cell Therapeutics (BCLI) hosting their ALS treatment webinar?
What is the purpose of BrainStorm's (BCLI) Phase 3b trial for NurOwn?
Who is the key speaker at BrainStorm's (BCLI) December 2024 ALS webinar?
What will be discussed at BrainStorm's (BCLI) December 2024 webinar?
